Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

2 years ago

WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused…

iZafe Group and Atea Sweden Have Entered into an Agreement with VGR in the Field of Welfare Technology

2 years ago

STOCKHOLM, SE / ACCESSWIRE / November 23, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB ("iZafe Group") announces that the…

Justera Secures Supply Agreement for Emart24 to Expand Global Reach

2 years ago

Toronto, Ontario--(Newsfile Corp. - November 23, 2023) - Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company")…

Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

2 years ago

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion…

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

2 years ago

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS…

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

2 years ago

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS…

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

2 years ago

Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug…

Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

2 years ago

SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…

Premier Health’s Subsidiary Canadian Health Care Agency Awarded Contracts Valued at $23m

2 years ago

MONTREAL, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a…

Bright Green Announces Third Quarter 2023 Financial Update and Milestone Progress

2 years ago

Bright Green has achieved several key milestones throughout the Quarter advancing progress against its strategic plan. Continued marketing of its…